Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 20/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 15/20 | 0.49 |
| ▸ | HTR2A | P28223 | 14/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12115136 | 0.78 | HTT (0.64) | — | |
| SCHEMBL12113756 | 0.76 | MAPT (0.41) | SLC6A4 | |
| SCHEMBL3483104 | 0.75 | SLC6A4 (0.58) | SLC6A4KCNH2HTR2ASLC6A2SLC6A3 | |
| SCHEMBL12964268 | 0.73 | SLC6A4 (0.59) | SLC6A4KCNH2HTR2ASLC6A2SLC6A3 | |
| Hydrochloric Acid SCHEMBL5391218 | 0.73 | SLC6A4 (0.57) | SLC6A4KCNH2HTR2ASLC6A2SLC6A3 | |
| SCHEMBL18588940 | 0.73 | SLC6A4 (0.55) | SLC6A4KCNH2HTR2ASLC6A2SLC6A3 | |
| SCHEMBL12305651 | 0.72 | MEN1 (0.67) | SLC6A4KCNH2HTR2A | |
| SCHEMBL15740357 | 0.72 | SLC6A4 (0.53) | SLC6A4KCNH2HTR2ASLC6A2SLC6A3 | |
| SCHEMBL20729353 | 0.72 | SLC6A4 (0.53) | SLC6A4KCNH2HTR2ASLC6A2SLC6A3 | |
| SCHEMBL5108078 | 0.72 | SLC6A4 (0.53) | SLC6A4KCNH2HTR2ASLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8053457-B2 | 3-imidazolyl-indoles for the treatment of proliferative diseases | NOVARTIS AG (CH) | 2011-11-08 | — | — | US | disclosed |
| US-20100125064-A1 | 3-Imidazolyl-Indoles for the Treatment of Proliferative Diseases | NOVARTIS AG (CH) | 2010-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100125064-A1 | 3-Imidazolyl-Indoles for the Treatment of Proliferative Diseases | MDM4, TP53, MDM2 | SLC6A4 2681/4885KCNH2 4415/4885HTR2A 1372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.